Info

NeuroLogic, Inc. (NLI) is a drug discovery company focused on practical and innovative solutions for Central Nervous System (CNS) disorders and diseases affecting attention, learning, and memory as well as memory disorders such as Alzheimer's disease (AD). Although the Company is clearly focused on discovery and development of therapeutics for learning and memory disorders, the Company expects to generate royalties from the first FDA approved diagnostic test for AD. NLI is completing a multi-centered, double-blind clinical trial (4Q01) with 600+ patients with Johns Hopkins University, and expects approval in the first quarter 02. This test will distinguish AD from non-AD dementias. The market (U.S.) for an FDA approved test is estimated to be 1.5MM tests/year. NLI expects to license the test to a large diagnostic/pharmaceutical company by 2002. The Company's platform science emerges from more than 30 years of research of Dr. Daniel Alkon, Chief Scientific Advisor to NLI and Scientific Director of the Blanchette Rockefeller Neurosciences Institute (BRNI). Dr. Alkon holds the Rockefeller Chair of Neuroscience. Previously, Dr. Alkon was Chief of the Laboratories of Adaptive Systems at the National Institutes of Health (NINDS), and over his career, he has published more than 300 papers in peer reviewed journals, authored books on learning and memory and holds several patents in the field of learning and memory. The insights Dr. Alkon developed over his career are now mature for product development for patients suffering from learning and memory disorders. In addition to the team he brought with him from the NIH and others recently recruited, Dr. Alkon is developing a global network of leading scientists to pursue the translation of cutting edge science into much needed drugs to improve cognition and memory. In addition to the extensive network of North American scientists, Dr. Alkon is assisting NLI in creating a global scientific advisory board with epicenters in North America, and Basel, Switzerland to capture the best ideas for drugs that enhance memory, and diminish suffering from neurological disorders affecting cognition. Prof. Gottfried Schatz (Biozentrum/Swiss Science and Technology Council) will chair the European Scientific Advisory Board (SAB) and provide guidance to NLI. Dr. Jeff Leighton (V.P. - Glaxo Pharmaceuticals, Founder/CEO of Genesis (acquired by Lilly), ICAgen, Inspire Pharmaceutical) is CEO of NLI and will establish a residence in Basel and manage the worldwide operation of the Company. The NLI proprietary drug discovery process is based on recent breakthrough insights into critical, specific, and rate limiting molecular targets discovered through a unique correlation of biochemical, biophysical, and behavioral efficacy. As a discovery company, these compounds will be developed through early proof of principle in humans (i.e., minimally through Phase I). This process combines applied clinical neuroscience with comprehensive multi-disciplinary basic neuroscience provided to NeuroLogic, in part, through it's license for intellectual property with the Blanchette Rockefeller Neurosciences Institute (BRNI), named after the late wife of John D. Rockefeller the III, who died from AD. Recent breakthroughs in the understanding of molecular and chemical events associated with attention, learning and memory have yielded numerous new validated biological targets for NLI that position the Company as first mover in the discovery of new (CNS) drug candidates that improve, or ameliorate disorders effecting learning and memory. The time for effective CNS pharmaceuticals is now, and NLI is poised to develop the first meaningful solutions for a variety of neurological conditions, and will control this space through its superior understanding of the mechanisms of learning and memory. NLI's approach emerges from detailed and comprehensive molecular "maps" that underlie basic mechanisms of learning and memory. These unique insights offer the Company proprietary opportunities to translate these new findings into novel drug targets. While NLI is learning new information about brain functions, we have identified a limited number of molecular "switches" that regulate these processes. This affords us a unique opportunity to address these "switches" to improve or enhance learning. Such molecular switches are providing targets for enhancing learning in animal models and by demonstrating efficient proof of principle, significantly reduce discovery risk. The Company further reduces risk using animal systems by demonstrating: Clear correlations of learning and memory systems in animals; Direct causal relationships established using anti-sense in living animals; Chemical leads based on predictive pharmacology and molecular events in living animals; Clinical diagnostic capability in humans. Now is the time to exploit and capture the leadership position in a market where innovative concepts in drugs have been inadequate to meet the demands of a large and growing market relating to disorders affecting learning and memory. This summary provides investors an understanding of how NLI integrates scientific leaders from around the world to work collaboratively toward the efficient discovery (and strategic value-added development) of new proprietary drugs as well as new applications for existing drugs (already approved for use in humans) that target CNS disorders affecting attention, learning and memory. Further, this summary provides a description of relevant markets, products and services; pipeline opportunities, management and global reach used for the efficient discovery of new CNS drugs.